Brief: Synact Pharma Announces Completion Of Dosing In Phase 2B Expand Study

SynAct Pharma AB

14/07/2023 07:10

July 14 (Reuters) - SynAct Pharma AB  SYNACT.ST :
    * SYNACT PHARMA ANNOUNCES THE COMPLETION OF DOSING IN THE
PHASE 2B
EXPAND STUDY OF RESOMELAGON (AP1189) IN EARLY SEVERE RHEUMATOID
ARTHRITIS PATIENTS

Source text for Eikon:  ID:nMFN40t6lk 
Further company coverage:  SYNACT.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))